Intrathecal enzyme replacement therapy: Successful treatment of brain disease via the cerebrospinal fluid
- 26 February 2007
- journal article
- research article
- Published by Elsevier BV in Molecular Genetics and Metabolism
- Vol. 91 (1), 61-68
- https://doi.org/10.1016/j.ymgme.2006.12.012
Abstract
No abstract availableKeywords
This publication has 23 references indexed in Scilit:
- A follow-up study of MPS I patients treated with laronidase enzyme replacement therapy for 6 yearsMolecular Genetics and Metabolism, 2007
- Penetration, diffusion, and uptake of recombinant human α-l-iduronidase after intraventricular injection into the rat brainMolecular Genetics and Metabolism, 2005
- Pharmacokinetic profile of recombinant human N‐acetylgalactosamine 4‐sulphatase enzyme replacement therapy in patients with mucopolysaccharidosis VI (Maroteaux–Lamy syndrome): a phase I/II studyActa Paediatrica, 2005
- Intrathecal enzyme replacement therapy reduces lysosomal storage in the brain and meninges of the canine model of MPS IMolecular Genetics and Metabolism, 2004
- Cord-Blood Transplants from Unrelated Donors in Patients with Hurler's SyndromeNew England Journal of Medicine, 2004
- Enzyme replacement therapy for mucopolysaccharidosis I: a randomized, double-blinded, placebo-controlled, multinational study of recombinant human α-L-iduronidase (laronidase)The Journal of Pediatrics, 2004
- Intracranial Injection of Recombinant Adeno-associated Virus Improves Cognitive Function in a Murine Model of Mucopolysaccharidosis Type VIIMolecular Therapy, 2001
- Long‐term outcome of Hurler syndrome following bone marrow transplantationAmerican Journal of Medical Genetics, 1993
- Replacement Therapy for Inherited Enzyme Deficiency — Macrophage-Targeted Glucocerebrosidase for Gaucher's DiseaseNew England Journal of Medicine, 1991
- REVERSAL OF CLINICAL FEATURES OF HURLER'S DISEASE AND BIOCHEMICAL IMPROVEMENT AFTER TREATMENT BY BONE-MARROW TRANSPLANTATIONThe Lancet, 1981